Program
Oxonic Acid
Also written as “S-1”, “S-1/Cisplatin” and “S-1, Irinotecan, Bevacizumab”.
Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Renal Insufficiency, led by 4 companies.
Drug pageOxonic Acid: every studyAll 181 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 190 open or running | phase 3since Jun 30, 2005 | Jun 30, 2005 | none ahead |
| TTY Biopharmits history only | 40 open or running | phase 2since Mar 26, 2015 | Jun 4, 2013 | none ahead |
| Innovent Biologicsits history only | 11 open or running | phase 2since Mar 16, 2026 | Mar 16, 2026 | Jun 30, 2030phase 2 · NCT07483567 |
| Sanofiits history only | 10 open or running | phase 3since Jan 16, 2008 | Jan 16, 2008 | none ahead |
Also a collaborator on its studies: Quintiles, United BioSource and Daiichi Sankyo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Otsuka only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2005First study: phase 3 study in Stomach NeoplasmsFirst studyNCT00400179 · 1,053 enrolled · United States, Canada
- Sep 7, 20053 phase 3 studies in Stomach NeoplasmsNCT00150670, NCT00152217, NCT00202969
- Jan 30, 2006Phase 3 study in Colorectal NeoplasmsNCT00284258 · 426 enrolled · Japan
- Nov 8, 20063 phase 1 studiesNCT00398424, NCT00398307, NCT00400023
- Jul 6, 2007Phase 3 study in Pancreatic NeoplasmsNCT00498225 · 834 enrolled · Japan, Taiwan
- Dec 5, 20073 phase 2 studiesNCT00569790, NCT00569699, NCT00569335
- Mar 31, 20084 phase 2 studiesNCT00652561, NCT00652054, NCT00651833 and 1 more
- Oct 9, 2008Phase 3 study in Uterine Cervical NeoplasmsNCT00770874 · 375 enrolled · Japan, Korea, Republic of, Taiwan
- Apr 30, 2009Phase 2 study in Colorectal NeoplasmsNCT00891332 · 73 enrolled · China, Japan
- Jan 26, 2011Phase 3 study in Stomach NeoplasmsNCT01285557 · 361 enrolled · United States, Argentina, Belgium and more
TargetBeta
“A modulator of 5-fluorouracil (5-FU) activity and inhibitor of the enzyme orotate phosphoribosyl-transferase (OPRT), with chemoprotective activity”NCIt, by rule
Studies
All 19 Otsuka leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01285557Stomach Neoplasms · United States, Argentina, Belgium and more | 3 | Terminated | Aug 15, 2014 | 361 |
| NCT00891332Colorectal Neoplasms · China, Japan | 2 | Completed | Jul 2011 | 73 |
| NCT00770874Uterine Cervical Neoplasms · Japan, Korea, Republic of, Taiwan | 3 | Completed | Dec 2015 | 375 |
| NCT00652561Advanced Non-Small Cell Lung Cancer | 2 | Completed | Nov 2007 | 57 |
| NCT00652054Pancreatic Neoplasms | 2 | Completed | Jun 2007 | 39 |
| NCT00651833Advanced Non-Small Cell Lung Cancer | 2 | Completed | Oct 2006 | 60 |
| NCT00651742Pancreatic Neoplasms | 2 | Completed | Jul 8, 2008 | 28 |
| NCT00569790Colorectal Neoplasms · Japan | 2 | Completed | Mar 2010 | 53 |
| NCT00569699Colorectal Neoplasms · Japan | 2 | Completed | Mar 2011 | 56 |
| NCT00569335Colonic Neoplasms · Japan | 2 | Completed | Mar 2010 | 52 |
| NCT00498225Pancreatic Neoplasms · Japan, Taiwan | 3 | Completed | Jul 2011 | 834 |
| NCT00400023Neoplasms · United States | 1 | Completed | May 2007 | 12 |
| NCT00398424Impaired Hepatic Function · United States | 1 | Completed | Nov 2008 | 24 |
| NCT00398307Renal Insufficiency · United States | 1 | Completed | Sep 2010 | 24 |
| NCT00284258Colorectal Neoplasms · Japan | 3 | Completed | Jul 2010 | 426 |
| NCT00202969Stomach Neoplasms · China | 3 | Completed | Jan 2007 | 180 |
| NCT00152217Stomach Neoplasms · Japan | 3 | Completed | May 2007 | 1,000 |
| NCT00150670Stomach Neoplasms · Japan | 3 | Completed | Dec 2006 | 300 |
| NCT00400179Stomach Neoplasms · United States, Canada | 3 | Completed | Mar 2008 | 1,053 |
How it is read
Names in the registry
- “S-1”, 8 entries
- “S-1/Cisplatin”, 3 entries
- “S-1, Irinotecan, Bevacizumab”, 2 entries
- “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry
- “S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 5 studies
- Pancreatic Neoplasms, 5 studies
- Colorectal Neoplasms, 5 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.